Journal
JOURNAL OF IMMUNOLOGY
Volume 189, Issue 7, Pages 3397-3403Publisher
AMER ASSOC IMMUNOLOGISTS
DOI: 10.4049/jimmunol.1201540
Keywords
-
Categories
Funding
- European Commission
Ask authors/readers for more resources
CD8(+) T cells have the potential to attack and eradicate cancer cells. The efficacy of therapeutic vaccines against cancer, however, lacks defined immune correlates of tumor eradication after (therapeutic) vaccination based on features of Ag-specific T cell responses. In this study, we examined CD8(+) T cell responses elicited by various peptide and TLR agonist-based vaccine formulations in nontumor settings and show that the formation of CD62L(-)KLRG1(+) effector-memory CD8(+) T cells producing the effector cytokines IFN-gamma and TNF predicts the degree of therapeutic efficacy of these vaccines against established s.c. tumors. Thus, characteristics of vaccine-induced CD8(+) T cell responses instill a predictive determinant for the efficacy of vaccines during tumor therapy. The Journal of Immunology, 2012, 189: 3397-3403.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available